Poliovirus receptor CD155 is up-regulated in muscle-invasive bladder cancer and predicts poor prognosis
Poliovirus receptor CD155 is up-regulated in muscle-invasive bladder cancer and predicts poor prognosis
复制标题
脊髓灰质炎病毒受体 CD155 在肌层浸润性膀胱癌中表达上调，可预测不良预后。
DOI：
10.1016/j.urolonc.2019.07.006
复制
发表时间：
2020-02-01
影响因子：
2.7
通讯作者：
Dai, Bo
中科院分区：
文献类型：
--
作者：
Zhang, Junyu;Zhu, Yu;Dai, Bo
目的：探讨CD155的表达模式并评估CD155在肌层浸润性膀胱癌（MIBC）中的预后价值。患者和方法：对复旦大学附属肿瘤医院和中山医院的228例接受根治性膀胱切除术的非转移性MIBC患者进行CD155的免疫组织化学染色和生存分析。在 TCGA 和 GSE13507 数据集中分析了 CD155 基因表达与肿瘤分期和生存的关联。结果：与匹配的正常尿路上皮相比，MIBC 中 CD155 显着上调，并且主要染色在肿瘤细胞膜上。在复旦大学MIBC队列中，CD155高表达与较短的无复发生存期（HR = 2.13，P < 0.001）和总生存期（HR = 2.49，P < 0.001）显着相关。 CD155表达、T分期和淋巴结状态是多变量分析中预测生存的独立因素。在 TCGA 数据集中，除年龄、T 分期和淋巴结状态外，CD155 高表达与较短的总生存期独立相关（HR = 1.74，P = 0.001）。此外，复旦大学 MIBC 队列的探索性分析表明，辅助化疗与 CD155 高肿瘤的 III 期和 IV 期疾病的较长无复发生存期和总生存期相关。结论：这些发现表明 CD155 是一个强有力的预后因素，可能有助于预测 MIBC 辅助化疗的益处。 (C) 2019 Elsevier Inc. 保留所有权利。
Objective: To investigate the expression pattern of CD155 and evaluate the prognostic value of CD155 in muscle-invasive bladder cancer (MIBC).Patients and methods: Immunohistochemical staining of CD155 and survival analysis were conducted on 228 nonmetastatic MIBC patients underwent radical cystectomy in cohorts from Fudan University Shanghai Cancer Center and Zhongshan Hospital. Association of CD155 gene expression with tumor stage and survival were analyzed in TCGA and GSE13507 dataset.Results: CD155 was significantly up-regulated in MIBC compared to matched normal urothelium and majorly stained on the membrane of tumor cells. In Fudan MIBC cohort, CD155 high expression was significantly correlated with shorter recurrence-free survival (HR = 2.13, P < 0.001) and overall survival (HR = 2.49, P < 0.001). CD155 expression, T stage, and lymph node status were independent factors for predicting survival in multivariate analysis. In TCGA dataset, CD155 high expression was independently associated with shorter overall survival (HR = 1.74, P = 0.001) beyond age, T stage, and lymph node status. Further, explorative analysis in Fudan MIBC cohort showed that adjuvant chemotherapy was associated with longer recurrence-free survival and overall survival in stage III and IV disease with CD155-high tumors.Conclusions: These findings suggest that CD155 is a robust prognostic factor and may help predict the benefit of adjuvant chemotherapy in MIBC. (C) 2019 Elsevier Inc. All rights reserved.